Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 44, 2014 - Issue 7
581
Views
28
CrossRef citations to date
0
Altmetric
Research Article

Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies

, , , &
Pages 615-626 | Received 28 Nov 2013, Accepted 20 Dec 2013, Published online: 08 Jan 2014

References

  • Alin MH, Ashton M, Kihamia CM, et al. (1996). Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. Br J Clin Pharmacol 41:587–92
  • Ashton M, Hai TN, Sy ND, et al. (1998a). Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Drug Metab Dispos Biol Fate Chem 26:25–7
  • Ashton M, Nguyen DS, Nguyen VH, et al. (1998b). Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. Clin Pharmacol Ther 63:482–93
  • Asimus S, Elsherbiny D, Hai TN, et al. (2007). Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. Fundam Clin Pharmacol 21:307–16
  • Atkins WM. (2005). Non-Michaelis–Menten kinetics in cytochrome P450-catalyzed reactions. Annu Rev Pharmacol Toxicol 45:291–310
  • Augustijns P, D'Hulst A, Van Daele J, Kinget R. (1996). Transport of artemisinin and sodium artesunate in Caco-2 intestinal epithelial cells. J Pharm Sci 85:577–9
  • Backonja MM, Irving G, Argoff C. (2006). Rational multidrug therapy in the treatment of neuropathic pain. Curr Pain Headache Rep 10:34–8
  • Bapiro TE, Egnell AC, Hasler JA, Masimirembwa CM. (2001). Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos Biol Fate Chem 29:30–5
  • Bapiro TE, Sayi J, Hasler JA, et al. (2005). Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans. Eur J Clin Pharmacol 61:755–61
  • Batty KT, Ilett KF, Davis TM. (2004). Protein binding and alpha: beta anomer ratio of dihydroartemisinin in vivo. Br J Clin Pharmacol 57:529–33
  • Chauret N, Gauthier A, Nicoll-Griffith DA. (1998). Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos Biol Fate Chem 26:1–4
  • Colussi D, Parisot C, Legay F, Lefevre G. (1999). Binding of artemether and lumefantrine to plasma proteins and erythrocytes. Eur J Pharm Sci Official J Eur Federation Pharm Sci 9:9–16
  • Elsherbiny DA, Asimus SA, Karlsson MO, et al. (2008). A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. J Pharm Pharmacodyn 35:203–17
  • Ericsson T, Masimirembwa C, Abelo A, Ashton M. (2012). The evaluation of CYP2B6 inhibition by artemisinin antimalarials in recombinant enzymes and human liver microsomes. Drug Metab Lett 6:247–57
  • Ezzet F, Mull R, Karbwang J. (1998). Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br J Clin Pharmacol 46:553–61
  • FDA (US Food and Drug Administration). (2012). Guidance for industry: drug interaction studies – study design, data analysis, implications for dosing, and labeling recommendations. Silver Spring (MD): US Food and Drug Administration, Center for Drug Evaluation and Research (CDER)
  • Gordi T, Huong DX, Hai TN, et al. (2002). Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens. Antimicrob Agents Chemother 46:1026--31
  • He F, Bi HC, Xie ZY, et al. (2007). Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: application to high-throughput inhibition screening of terpenoids. Rapid Commun Mass Spectrom 21:635–43
  • Ito K, Brown HS, Houston JB. (2004). Database analyses for the prediction of in vivo drug–drug interactions from in vitro data. Br J Clin Pharmacol 57:473–86
  • Ito K, Iwatsubo T, Kanamitsu S, et al. (1998). Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 38:461–99
  • Kanamitsu S, Ito K, Sugiyama Y. (2000). Quantitative prediction of in vivo drug–drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res 17:336–43
  • Kim MJ, Kim H, Cha IJ, et al. (2005). High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 19:2651–8
  • Mihara K, Svensson US, Tybring G, et al. (1999). Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19. Fundam Clin Pharmacol 13:671–5
  • Na-Bangchang K, Krudsood S, Silachamroon U, et al. (2004). The pharmacokinetics of oral dihydroartemisinin and artesunate in healthy Thai volunteers. Southeast Asian J Trop Med Public Health 35:575–82
  • Pelkonen O, Turpeinen M, Hakkola J, et al. (2008). Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 82:667–715
  • Perdaems N, Blasco H, Vinson C, et al. (2010). Predictions of metabolic drug–drug interactions using physiologically based modelling: two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. Clin Pharmacokinet 49:239–58
  • Shou M, Lin Y, Lu P, et al. (2001). Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab 2:17–36
  • Sidhu JS, Ashton M, Huong NV, et al. (1998). Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria. Br J Clin Pharmacol 45:347–54
  • Simonsson US, Jansson B, Hai TN, et al. (2003). Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin Pharmacol Ther 74:32–43
  • Stresser DM. (2004). High-throughput screening of human cytochrome P450 inhibitors using fluorometric substrates. In: Yan Z, Caldwell GW, eds. Optimization in drug-discovery – in vitro methods. Spring House (PA): Johnson & Johnson Pharmaceutical Research & Development, 215–30
  • Stresser DM, Blanchard AP, Turner SD, et al. (2000). Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos Biol Fate Chem 28:1440–8
  • Svensson US, Ashton M, Trinh NH, et al. (1998). Artemisinin induces omeprazole metabolism in human beings. Clin Pharmacol Ther 64:160–7
  • Turpeinen M, Korhonen LE, Tolonen A, et al. (2006). Cytochrome P450 (CYP) inhibition screening: comparison of three tests. Eur J pharm Sci Official J Eur Federation Pharm Sci 29:130–8
  • van Agtmael MA, Cheng-Qi S, Qing JX, et al. (1999a). Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. Int J Antimicrob Agents 12:151–8
  • van Agtmael MA, Eggelte TA, van Boxtel CJ. (1999b). Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medication. Trends Pharmacol Sci 20:199–205
  • White NJ, van Vugt M, Ezzet F. (1999). Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet 37:105–25
  • WHO (World Health Organization). (2010). Guidelines for the treatment of malaria, 2nd ed. Geneva, Switzerland: World Health Organization
  • Xing J, Kirby BJ, Whittington D, et al. (2012). Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes. Drug Metab Dispos Biol Fate Chem 40:1757–64
  • Zanger UM, Turpeinen M, Klein K, Schwab M. (2008). Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392:1093–108

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.